Achievements
Dr. Hashimoto's (B01 Representative) paper was published in Life Science Alliance.
Dr. Hashimoto's (B01 Representative) paper has been published in Life Science Alliance. It has been revealed that 3pEAβ1-42, an Aβ species important in the formation of amyloid plaques, is promoted by the decrease in neprilysin, an Aβ metabolic enzyme.
Iwata N, Tsubuki S, Sekiguchi M, Watanabe-Iwata K. Matsuba Y, Kamano N, Fujioka R, Takamura R, Watamura N, Kakiya N, Mihira N, Morito T, Shirotani K, MA Mann D, Robinson CA, Hashimoto S, Sasaguri H, Saito T, Higuchi M, Saido TC. Metabolic resistance of Aβ3pE-42, a target epitope of the anti-Alzheimer therapeutic antibody, donanemab. Life Science Alliance 7(12) e202402650.
https://www.life-science-alliance.org/content/7/12/e202402650
Dr. Tsukakoshi's (C01 Representative) paper was published in Advanced Science.
Dr. Tsukakoshi's (C01 Representative) paper has been published in Advanced Science. We have developed a new detection system that combines enzyme-modified antibodies and DNAzyme-modified aptamers, and uses a continuous enzyme reaction that occurs only when each is simultaneously bound to a virus particle. Tsukagoshi has contributed to the development of the aptamer.
Miura, D., Hayashi, W, Hirano, K., Sasaki, I., Tsukakoshi, K., Kakizoe, H., Asai, S, Vavricka, C.J., Takemae, H., Mizutani, T., Tsugawa, W., Sode, K., Ikebukuro, K., and Asano, R. Proximity-Unlocked Luminescence by Sequential Enzymatic Reactions from Antibody and Antibody/Aptamer (PULSERAA): A Platform for Detection and Visualization of Virus-Containing Spots. (2024) Adv Sci (Weinh). e2403871.
Dr. Hashimoto's (B01 Representative) paper was published in FEBS Letters.
Dr. Hashimoto's (B01 Representative) paper was published in FEBS Letters.
We found that oxidative stress due to reduced glutathione levels leads to increased Aβ42 and promoted tau pathology.
Hashim KN, Matsuba Y, Takahashi M, Kamano N, Tooyama I, Saido TC, Hashimoto S*. Neuronal glutathione depletion elevates the Aβ42/Aβ40 ratio and tau aggregation in Alzheimer's disease mice. FEBS letters 598(13) 1576-1590.
Dr. Tsukakoshi's (C01 Representative) paper was published in Talanta.
Dr. Tsukakoshi's (C01 Representative) paper was published in Talanta.
This is research on the development of a FRET-type sensing system using an aptamer that specifically binds to the antibody drug bevacizumab.
Yamada T, Tsukakoshi K, Furusho A, Sugiyama E, Mizuno H, Hayashi H, Yamano T, Kumobayashi H, Hasebe T, Ikebukuro K, Toyo'oka T, Todoroki K. Simple and fast one-step FRET assay of therapeutic mAb bevacizumab using anti-idiotype DNA aptamer for process analytical technology. Talanta. 2024 Sep 1;277:126349.
https://www.sciencedirect.com/science/article/pii/S0039914024007288?via%3Dihub